Remoxipridum [Inn-Latin]

• Antipsychotics
• Dopamine Antagonists
• ATC:N05AL04

• Remoxiprida [Inn-Spanish]
• Remoxipride [Usan:Ban:Inn]
• Remoxipridum [Inn-Latin]
• Romoxipride

• No information avaliable

C₁₆H₂₃BrN₂O₃

No information avaliable

No information avaliable

371.269 g/mol

No information avaliable

74 mg/L

Solid

3.511

Tablet

For the treatment of schizophrenia.

Remoxipride, a substituted benzamide, is a selective D2 receptor antagonist. It has been shown to be effective in the treatment of schizophrenia. Some antipsychotics block domapinergic receptors as well as cholinergic, noradrenergic and histaminergic receptors. Remoxipride was developed to act specifically on the dopamine D2 receptor. As a consequence, several undesired side effects can occur. Patients often feel they are not taking any antipsychotic drug. It has a potent affinity for the sigma receptor, but it is unclear whether it is a sigma agonist or antagonist. The contribution of this property to its clinical profile is unknown. Blocking the D2 dopamine receptor is known to cause relapse in patients that have achieved remission from depression, and such blocking also counteracts the effectiveness of SSRI medication.

Rapidly absorbed. Absolute bioavailability is 90%.

No information avaliable

No information avaliable

Humans and other mammals